Company intelligence / Profile preview

Indigene Pharmaceuticals

Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

The company’s lead drug (IG-MD-009) reached clinical trials in type 2 diabetes; other programs remained at pending/preclinical stage. No marketed products and no published positive pivotal clinical results. Company dissolved.

Therapeutic areas: OncologyImmunologyEndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Indigene Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Indigene Pharmaceuticals.

Explore the full profile